摘要
目的:探讨AICARFT、mTOR在人肺腺癌亲本株A549及培美曲塞诱导人肺腺癌耐药株A549/PEM中表达变化及意义。方法流式细胞术检测A549及A549/PEM细胞周期分布, RT-PCR、Western blot分别检测AICARFT、mTOR在A549及A549/PEM的mRNA及蛋白表达变化。结果流式细胞术检测细胞周期提示处于S期的A549/PEM较A549明显增多,分别为(36.61±1.36)%和(27.16±1.08)%( P=0.001);RT-PCR检测mRNA示A549/PEM的AICARFT及mTOR基因表达与A549相比均表达上调(P<0.05);Western blot检测蛋白示A549/PEM的AICARFT及mTOR蛋白表达与A549相比均表达上调(P<0.05)。结论人肺腺癌培美曲塞获得性耐药细胞株出现细胞周期重分布,培美曲塞获得性耐药可能与AICARFT、mTOR表达上调相关。
Objective To investigate the expression of AICARFT and mTOR in lung adenocarcinoma cell line A549 and pemetrexed resistant human lung adenocarcinoma cell line A549/PEM.Methods The distri-bution of cell cycle was evaluated by flow cytometry assay.The expression of AICARFT and mTOR in A549 and A549/PEM were detected by RT-PCR and Western blot.Results Flow cytometry analysis showed that S phase in A549/PEM was higher than that in A549((36.61 ±1.36)%vs(27.16 ±1.08)%(P=0.001)).mRNA over expression of AICARFT and mTOR in A549/PEM were detected by RT-PCR(P〈0.05).Protein over expres-sion of AICARFT and mTOR in A549/PEM were detected by Western blot.(P〈0.05).Conclusion High level of AICARFT and mTOR may be connected with pemetrexed acquired drug resistance in lung adenocarcinoma.The cycle of pemetrexed resistant human lung adenocarcinoma cancer cell line A549/PEM is redistributed.
出处
《实用肿瘤学杂志》
CAS
2015年第4期337-341,共5页
Practical Oncology Journal